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Background: We studied the association of inflammatory biomarkers including C-reactive protein (CRP), tumor
necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) with chronic kidney disease (CKD).
Methods: We conducted a case–control study among 201 CKD patients and 201 community-based controls in the
greater New Orleans area. CKD was defined as estimated-glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 or
albuminuria ≥30 mg/24-h. Serum CRP, TNF-α, and IL-6 were measured using standard methods. Multivariable
regression models were used to examine associations between the inflammatory biomarkers and CKD adjusting
for important CKD risk factors, history of cardiovascular disease, and use of antihypertensive, antidiabetic, and
lipid-lowering agents and aspirin.
Results: The multivariable-adjusted medians (interquartile-range) were 2.91 (1.47, 5.24) mg/L in patients with
CKD vs. 1.91 (0.99, 3.79) mg/L in controls without CKD (p = 0.39 for group difference) for CRP; 1.86 (1.51, 2.63) pg/mL vs.
1.26 (1.01, 1.98) pg/mL (p < 0.0001) for TNF-α; and 2.53 (1.49, 4.42) pg/mL vs. 1.39 (0.95, 2.15) pg/mL (p = 0.04) for IL-6,
respectively. Compared to the lowest tertile, the highest tertile of TNF-α (OR 7.1, 95 % CI 3.2 to 15.5) and IL-6 (OR 2.5,
95 % CI 1.1 to 5.5) were significantly associated with higher odds of CKD in multivariable-adjusted models. Additionally,
higher TNF-α and IL-6 were independently and significantly associated with lower eGFR and higher albuminuria.
Conclusions: Our data suggest that TNF-α and IL-6, but not CRP, are associated with the prevalence and severity of
CKD, independent from established CKD risk factors, history of cardiovascular disease, and use of antihypertensive,
antidiabetic, and lipid-lowering agents and aspirin.
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Chronic kidney disease (CKD) is highly prevalent world-
wide and a major risk factor for end-stage renal disease
(ESRD), cardiovascular disease (CVD), and premature
death [1]. Systemic inflammation has been associated with
increased risk of CVD and mortality in patients with CKD
[2]. For example, C-reactive protein (CRP), an acute phase
reactant, is associated with all-cause and CVD mortality in
patients with ESRD [3–7]. Tumor necrosis factor-alpha* Correspondence: jchen@tulane.edu
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unless otherwise stated.(TNF-α) and interleukin-6 (IL-6), key cytokines that
mediate both acute and chronic inflammation, are asso-
ciated with CVD morbidity and mortality in the general
population [8–10] and in predialysis and dialysis pa-
tients [11, 12]. However, several epidemiological studies
have reported inconsistent findings on the associations
of CRP, TNF-α, IL-6, and CKD. For instance, Gupta and
colleagues reported that CRP was inversely associated with
estimated glomerular filtration rate (eGFR) but not associ-
ated with urine albumin-to-creatinine ratio in the Chronic
Renal Insufficiency Cohort (CRIC) Study [13]. Upadhyay
and colleagues reported that multivariable-adjusted means
of TNF-α and IL-6, but not CRP, were significantly elevated
among patients with CKD in the Framingham Offspringis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ation of CRP, TNF-α, and IL-6 with CKD is independent of
traditional CKD risk factors, history of CVD, and use of
antihypertensive, antidiabetic, and lipid-lowering agents
and aspirin.
The objective of this case–control study is to investigate
the association of circulating CRP, TNF-α, and IL-6 with
CKD after adjusting for multiple important risk factors, in-
cluding current treatment for hypertension, hyperlipidemia,
diabetes, and CVD. In addition, we examine the association
between circulating CRP, TNF-α, and IL-6 with CKD sever-
ity, measured by eGFR and urinary albumin excretion.
Methods
Study participants
We recruited 201 CKD patients and 201 controls with-
out CKD in the greater New Orleans, Louisiana area
from 2007 to 2010. CKD patients were age 21 to 74 years
and recruited from nephrology and internal medicine
clinics in the study area. CKD was defined as eGFR
<60 ml/min/1.73 m2 or the presence of albuminuria
(≥30 mg/24-h) for three or more months. Patients with
acute kidney injury were excluded. In addition, patients
were excluded if they had a history of chronic dialysis,
kidney transplant, immunotherapy in the past six
months, chemotherapy within the past two years, or
current clinical trial participation that may have an impact
on CKD. Additional exclusion criteria were history of HIV
or AIDS and inability or unwillingness to give informed
consent. Control participants were recruited through mass
mailings to residents aged 21–74 years living in the same
area according to zip code.
Tulane University Internal Review Board approved this
study, and written informed consent was obtained at the
screening visit from all study participants. This study
adheres to the Declaration of Helsinki.
Study measurements
A standard questionnaire was administered by trained
staff at a clinical visit to obtain demographic information,
lifestyle risk factors (including cigarette smoking and
alcohol ingestion), self-reported history of CVD, dia-
betes, hypercholesterolemia, and hypertension, as well
as the use of antihypertensive, lipid-lowering, and anti-
diabetic medications.
Three blood pressure (BP) measurements were obtained
at a clinical visit by trained and certified staff according to
a common protocol adapted from procedures recom-
mended by the American Heart Association [15]. A stand-
ard mercury sphygmomanometer was used, and one of
four cuff sizes (pediatric, regular adult, large, or thigh)
was chosen on the basis of the circumference of the
participant’s arm. Body height and weight were ob-
tained by trained staff and used to calculate body massindex (BMI =weight in kg/height2 in m) and body surface
area using Mosteller’s formula [(weight in kg × height
in cm)/3600]1/2 [16].
An overnight fasting blood sample was collected to
measure plasma glucose, serum creatinine, cholesterol,
and triglycerides. A 24-h urinary sample was collected to
measure creatinine and albumin. Serum cholesterol and
triglyceride levels were assayed using an enzymatic pro-
cedure on the Hitachi 902 automatic analyzer (Roche
Diagnostics, Indianapolis, IN, USA). Serum glucose was
measured using a hexokinase enzymatic method (Roche
Diagnostics, Indianapolis, IN, USA). Serum creatinine was
measured using the Roche enzymatic method (Roche–
Hitachi P-Module instrument with Roche Creatininase
Plus assay, Hoffman-La Roche, Basel, Switzerland). Urin-
ary concentrations of albumin and creatinine were mea-
sured with a DCA 2000 Analyzer (Bayer AG, Leverkusen,
Germany). eGFR was estimated from serum creatinine,
sex, age, and race using the CKD-Epi equation [17].
Serum levels of CRP were measured by a high-
sensitivity latex-enhanced immunonephelometric assay
(Roche Diagnostics, Indianapolis, IN). The assay has a
sensitivity of 0.02 mg/L and an intra-assay coefficient of
variation (CV) of <1.0 % and an inter-assay CV of 3.7 %.
Serum levels of IL-6 were measured by a commercially
available ELISA (Quantikine HS human IL-6 Immuno-
assay kit, R&D System, Minneapolis, MN). The detect-
able limit for IL-6 is 0.039 pg/mL, the intra-assay CV is
from 6.9 % to 7.8 %, and the inter-assay CV is from
6.5 % to 9.6 %. Serum TNF-α levels were measured by a
commercially available ELISA (Quantikine HS human
TNF-α Immunoassay kit, R & D Systems, Minneapolis,
MN). The detectable limit for TNF-α is 0.12 pg/mL, the
intra-assay CV is from 5.3 % to 8.8 %, and the inter-
assay CV is from 10.8 % to 16.7 %.
Statistical analysis
Medians and interquartile ranges for serum CRP, IL-6,
and TNF-α were calculated for CKD patients and con-
trols, and the Mann–Whitney U test was used to test
differences in the unadjusted medians. Quantile regres-
sion was used to obtain adjusted medians (interquartile
ranges) and the Wald test was used to test differences in
the adjusted medians between CKD patients and con-
trols [18]. These analyses were adjusted for age, gender,
race, high-school education, physical activity, current
cigarette smoking, weekly alcohol drinking, body-mass
index, LDL-cholesterol, plasma glucose, systolic blood
pressure, history of CVD, use of antihypertensive, anti-
diabetic, and lipid-lowering agents, and aspirin.
Multivariate logistic regression was used to obtain ad-
justed odds ratios comparing the higher tertiles of CRP,
IL-6, and TNF-α levels to the lowest tertile between
CKD patients and controls. Serum tertile levels were








Age, yrs 55.9 ± 9.9 52.5 ± 10.0 0.0007
Male, % 55.2 45.3 0.05























32.2 ± 7.8 28.9 ± 6.4 <0.0001
Systolic blood
pressure, mmHg
132.2 ± 21.0 122.0 ± 14.7 <0.0001
Diastolic blood
pressure, mmHg
77.2 ± 13.5 77.6 ± 9.4 0.77
Plasma glucose,
mg/dL
119.9 ± 46.7 103.4 ± 35.4 <0.0001
LDL-cholesterol,
mg/dL
103.3 ± 45.9 118.2 ± 30.2 <0.0001
HDL-cholesterol,
mg/dL
50.3 ± 15.6 57.7 ± 18.0 <0.0001





5.9 (4.1, 11.4) <0.0001
Mean ± standard deviation, percentage, or median (inter-quartile range)
LDL low-density lipoprotein; HDL high-density lipoprotein; eGFR estimated-
glomerular filtration rate; and CVD cardiovascular disease
aModerate or heavy physical activity at least twice per week









CRP, mg/L (IQR) 2.80 (1.13, 5.61) 1.49 (0.75, 3.65) <0.0001
TNF-α, pg/mL (IQR) 1.82 (1.5, 2.51) 1.27 (0.99, 1.81) <0.0001
IL-6, pg/mL (IQR) 2.46 (1.32, 4.54) 1.24 (0.88, 2.2) <0.0001
IQR = inter-quartile range; CRP = C-reactive protein; TNF-α = tumor necrosis factor al
aAdjusted for age, gender, race, high-school education, physical activity, current cig
plasma glucose, systolic blood pressure, history of cardiovascular disease, antihyp
aspirin use
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In addition, multivariable linear regression was used to
examine the association of serum levels of CRP, IL-6,
and TNF-α with eGFR and albuminuria after adjust-
ment for the previously mentioned covariates. Log
transformations were used for CRP, IL-6, TNF-α, and
urinary albumin levels, because they were not nor-
mally distributed. We did not impute missing data. All
analyses were performed using SAS version 9.2 statis-
tical software (Cary, NC).
Our study was designed to have an 80 % statistical
power to detect an odds ratio of 1.77 at a 2-sided sig-
nificance level of 0.05 when the cases and controls
were compared by the tertile of biomarkers. In
addition, we have an 80 % statistical power to detect a
mean difference of 0.3 standard deviations of bio-
markers between the cases and controls at a 2-sided
significance level of 0.05.Results
The general characteristics of study participants by CKD
status are presented in Table 1. Patients with CKD had a
mean eGFR of 43.4 mL/min/1.73 m2 compared to
96.7 mL/min/1.73 m2 among controls without CKD.
Among 201 CKD patients, 5 were stage-1, 33 stage-2,
104 stage-3, 49 stage-4, and 10 stage-5. Median urinary
albumin excretion was 74.5 mg/24 h in CKD patients
and 5.9 mg/24 h in controls. Those with CKD were
older, less educated, and less likely to drink alcohol or
engage in regular physical activity compared to those
without CKD. In addition, they were more likely to have
a history of CVD, hypertension, diabetes, and hyperchol-
esterolemia. Mean BMI, systolic BP, and serum glucose
levels were significantly higher, while LDL- and HDL-
cholesterol were lower in CKD patients compared to
controls.
The median serum levels of CRP, IL-6, and TNF-α
were significantly higher in patients with CKD compared
to controls. After adjusting for important covariables,
the medians of IL-6 and TNF-a, but not CRP, remained







2.91 (1.47, 5.24) 1.91 (0.99, 3.79) 0.39
1.86 (1.51, 2.63) 1.26 (1.01, 1.98) <0.0001
2.53 (1.49, 4.42) 1.39 (0.95, 2.15) 0.04
pha; IL-6 = interleukin 6
arette smoking, weekly alcohol drinking, body-mass index, LDL-cholesterol,
ertensive treatment, antidiabetic treatment, lipid lowering treatment, and
Table 3 Odds ratios of chronic kidney disease associated with





OR (95 % CI) P-value
for trend
OR (95 % CI) P-value
for trend
CRP ( mg/L)
≤1.1 1.0 (ref) 0.0002 1.0 (ref) 0.15
>1.1-3.3 1.3 (0.8-2.2) 1.2 (0.6-2.5)
>3.3 2.7 (1.6-4.1) 1.8 (0.8-3.9)
TNF-α (ng/mL)
≤1.3 1.0 (ref) <0.0001 1.0 (ref) <0.0001
>1.3-1.9 6.6 (3.7-11.7) 5.8 (2.7-12.7)
>1.9 7.8 (4.4-13.8) 7.1 (3.2-15.5)
IL-6 (μg/mL)
≤1.2 1.0 (ref) <0.0001 1.0 (ref) 0.02
>1.2-2.6 1.7 (1-2.8) 1.1 (0.5-2.3)
>2.6 5.0 (2.8-8.6) 2.5 (1.1-5.5)
CI confidence interval; CRP C-reactive protein; TNF-α tumor necrosis factor
alpha; IL-6 interleukin 6
aAdjusted for age, gender, race, high-school education, physical activity,
current cigarette smoking, weekly alcohol drinking, body-mass index, LDL-
cholesterol, plasma glucose, systolic blood pressure, history of cardiovascular
disease, antihypertensive treatment, antidiabetic treatment, lipid lowering
treatment, and aspirin use
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intervals) of CKD comparing the higher two tertiles to
the lowest tertile of the serum inflammatory biomarker
levels from the multivariate-adjusted logistic regression
analyses are presented in Table 3. The higher levels of
TNF-α and IL-6, but not CRP, were significantly asso-
ciated with odds of CKD after adjusting for multiple
confounding factors.
In multivariable-adjusted linear regression analyses,
serum levels of TNF-α and IL-6 were inversely and signifi-
cantly related to eGFR and positively related to urinary
albumin excretion (Table 4). On the other hand, serum
CRP level was not significantly associated with either
eGFR or urine albumin excretion.Table 4 Multivariable-adjusted regression coefficients (95 % confide
albumin associated with a one standard deviation difference in infla
Inflammatory
biomarkers (SD)
Estimated-glomerular filtration rate, mL/m
β (95 % CI)
CRP (Log,1.33 mg/L) −1.27 (−4.11 to 1.58)
TNF-α (Log,0.69 ng/mL) −5.02 (−7.56 to −2.47)
IL-6 ( Log, 0.9 ng/mL) −4.69 (−7.65 to −1.73)
Adjusted for age, gender, race, high-school education, physical activity, current ciga
plasma glucose, systolic blood pressure, history of cardiovascular disease, antihyp
aspirin use
SD standard deviation; log log-transformation; CI confidence interval; CRP C-reactiveDiscussion
The present study shows that inflammatory biomarkers
TNF-α and IL-6 are significantly elevated in patients
with CKD compared to controls without CKD. In
addition, TNF-α and IL-6 are significantly and positively
associated with the severity of CKD, measured by eGFR
and urinary albumin excretion. These associations are
independent of established risk factors for CKD, his-
tory of CVD, and use of antihypertensive, antidiabetic,
and lipid-lowering agents, as well as aspirin. In this
study, serum level of CRP is not independently associ-
ated with CKD.
CRP is a well-recognized risk factor for CVD and mor-
tality in the general population as well as in patients
with ESRD [3–7, 19]. However, our study indicates that
circulating CRP level was not significantly elevated in
pre-dialysis CKD patients after accounting for estab-
lished CKD risk factors, history of CVD, and use of anti-
hypertensive, antidiabetic, and lipid-lowering agents, and
aspirin. This finding is consistent with several previous
reports [14, 20–22]. In addition, our study reports that
serum CRP was not associated with eGFR or albumin-
uria in multiple linear regression models. In contrast, a
previous cross-sectional epidemiological study suggested
that CRP was associated with eGFR but not urine
albumin-to-creatinine ratio among patients with CKD
[13]. However, two longitudinal epidemiologic studies
also suggested that CRP was not associated with the
risk of developing CKD [23, 24]. Taken together, these
findings suggest that CRP is not an independent risk
factor for CKD.
Our study shows that circulating TNF-α and IL-6
levels are significantly higher in CKD patients compared
to controls and the levels of TNF-α and IL-6 are inde-
pendently associated with the severity of CKD. These
findings are consistent with those of previous large epi-
demiological studies [13, 14]. The longitudinal study by
Shankar et al. also suggested that TNF-α receptor 2 and
IL-6 levels were positively associated with the risk of de-
veloping CKD [23]. However, it is possible that albumin-
uria selectively activates cytokines and elevates TNF-αnce intervals) of estimated-glomerular filtration rate and urinary
mmatory biomarkers
in/1.73 m2 Log (urinary albumin, mg/24-h)
P-value β (95 % CI) P-value
0.38 0.11 (−0.08 to 0.29) 0.27
0.0001 0.27 (0.1 to 0.44) 0.002
0.0028 0.35 (0.16 to 0.54) 0.0003
rette smoking, weekly alcohol drinking, body mass index, LDL-cholesterol,
ertensive treatment, antidiabetic treatment, lipid lowering treatment, and
protein; TNF-α tumor necrosis factor alpha; IL-6 interleukin 6
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clearance of these cytokines in patients with CKD [25].
Therefore, future studies should investigate whether
the relationships of TNF-α and IL-6 with proteinuria
are causal.
The current study is noteworthy because it reports
that TNF-α and IL-6, but not CRP, are significantly associ-
ated with the prevalence and severity of CKD, independ-
ent of established risk factors, history of CVD, and use of
antihypertensive, antidiabetic, and lipid-lowering agents,
as well as aspirin. Careful measures of study exposure
and outcome variables in this study allowed for precise
estimation of the association. In addition, controls were
selected from the community, which should reduce
potential selection bias. Furthermore, the study participants
included a racially diverse group with variable degrees
of renal function and urine albumin excretion. Potential
limitations of this study should be noted. First, this
study cannot establish a temporal relationship or make
causality inferences due to its cross-sectional, observational
nature. Second, the study included a single measurement of
the proinflammatory cytokines, which may not represent
average levels of these biomarkers over time. However, pa-
tients with acute kidney injury were excluded from the
present study. In addition, serum creatinine-based eGFR
was used to define kidney function in our study. The
use of cystatin C-based or cystatin- and creatinine-
based eGFR might provide a better assessment of kidney
function regarding its predictive value for the risks of
death and ESRD [26]. Finally, we were not able to
analyze the association between inflammatory markers
and subtype of CKD by different causes because renal
biopsy data were not available in our study.
Conclusions
Our study findings suggest that TNF-α and IL-6, but not
CRP, are associated with the prevalence and severity of
CKD independent of established CKD risk factors, history
of CVD, and use of antihypertensive, antidiabetic, and
lipid-lowering agents and aspirin. Further studies are
warranted to investigate the role of inflammatory bio-
markers in the etiology of CKD and their predictive
value for advanced CVD and ESRD events among patients
with CKD.
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